Progynova Tablets

Progynova (Estradiol Valerate Tablets) - Product Information

Progynova (Estradiol Valerate Tablets) is used as a Hormone Replacement Therapy (HRT) for the treatment of menopausal complaints after the cessation of monthly bleeding, or after surgical removal of the ovaries (oophorectomy). HRT therapy with this medicine prevents discomfort caused by diminished circulating estrogen and progesterone hormones, and in the case of the surgically or prematurely menopausal and may reduce the incidence of dementia.
Hormone Replacement Therapy involves the use of one or more of a group of medications called Estrogens, Progesterone or Progestins designed to artificially boost hormone levels.

Progynova 1 mg and 2 mg tablets manufactured by Zydus Healthcare, India are available at our online pharmacy in ready stock. We also have in stock Generic Alesse (Ovral-L by Wyeth) which is a combined oral contraceptive tablet containing 0.03 mg Ethinyl Estradiol and 0.15 mg Levonorgestrel.

Name of the Drug

We supply original Progynova Tablets manufactured by Zydus Healthcare.

Manufacturer of Progynova Tablets

  Zydus Healthcare
Marketed by Bayer Pharmaceuticals Pvt. Ltd. (Bayer Zydus Pharma)
Website: www.bayer.in

Active Ingredient present in Progynova Tablets

The active ingredient present in Progynova tablets is Estradiol Valerate, also known as Oestradiol Valerate.

Uses of Progynova Tablets

Progynova tablets are a medical treatment for surgically menopausal (after surgical removal of the ovaries), perimenopausal and postmenopausal women. During the menopause, the quantity of the estrogen produced by a woman's body decreases. This could cause symptoms such as hot flushes, sweats, sleep disturbances, depressive moods, irritability, dizziness, headaches as well as vaginal dryness and burning. Progynova alleviates these symptoms after menopause. Relief of symptoms occurring after menopause if your symptoms seriously hinder your daily life.

If you are at an increased risk of fractures due to osteoporosis and other medicines are not suitable for you, you can use Progynova to prevent osteoporosis after menopause. Progynova tablets are also used for the treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease and treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).

Progynova (Estradiol Valerate Tablets) - Dosage

When estrogen (Progynova tablets) is prescribed for a postmenopausal woman with a uterus, a progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. The dosage of Progynova (Estradiol Valerate Tablets) for various indications is given below.

For treatment of moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause, the lowest dose and regimen that will control symptoms must be chosen and medicine should be stopped as soon as possible. Attempts to discontinue or taper the medicine should be made at 3-month to 6-month intervals. The usual starting dosage range is 1 mg to 2 mg daily of Estradiol adjusted as necessary to control presenting symptoms. The minimal effective dose for maintenance therapy should be determined by titration. Administration should be cyclic (e.g., 3 weeks on and 1 week off).

For treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.
Treatment is usually initiated with a dose of 1 mg to 2 mg daily of estradiol, adjusted as necessary to control presenting symptoms; the minimal effective dose for maintenance therapy should be determined by titration.

For treatment of breast cancer, for palliation only, in appropriately selected women and men with metastatic disease.
Suggested dosage is 10 mg three times daily for a period of at least three months.

For treatment of advanced androgen-dependent carcinoma of the prostate, for palliation only.
Suggested dosage is 1 mg to 2 mg three times daily. The effectiveness of therapy can be judged by phosphatase determinations as well as by symptomatic improvement of the patient.

For prevention of osteoporosis.
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy with this medicine must be considered only for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. The lowest effective dose of Progynova has not been determined.

Progynova (Estradiol Valerate Tablets) Storage

Store Progynova (Estradiol Valerate tablets) at controlled room temperature (68°F to 77°F, 20°C to 25°C). Protect from light.

Progynova Tablets Contraindications

Progynova tablets are contraindicated in patients with a hypersensitivity to Estradiol Valerate or any inactive ingredient present in Progynova tablets. Progynova tablets are also contraindicated in the following cases:

• Pregnancy or lactation
• Undiagnosed vaginal bleeding
• Known or suspected cancer of the breast
• Known or suspected premalignant conditions or malignancies, if sex steroid-influenced
• Presence or history of liver tumours (benign or malignant)
• Severe hepatic disease
• Acute arterial thromboembolism (myocardial infarction, stroke) or a recent history of these conditions
• Active deep venous thrombosis, thromboembolic disorders, thrombophlebitis, or a documented history of these conditions
• A high risk of venous or arterial thrombosis
• Hereditary or acquired predisposition to venous thrombosis (e.g. antithrombin III deficiency)
• Severe hypertriglyceridamia

Warnings and Precautions

Estrogen and estrogen/progestin therapy has been associated with an increased risk of cardiovascular events such as myocardial infarction and stroke, as well as venous thrombosis and pulmonary embolism (venous thromboembolism or VTE). In case any of these occur or be suspected, estrogens should be discontinued immediately.

In the Women's Health Initiative (WHI) study, an increase in the number of myocardial infarctions and strokes has been observed in women receiving CE compared to placebo.

In the Women's Health Initiative (WHI) study, an increase in VTE has been observed in women receiving CE compared to placebo.

Large doses of estrogen (5 mg conjugated estrogens per day), comparable to those used to treat cancer of the prostate and breast, have been shown in a large prospective clinical trial in men to increase the risks of nonfatal myocardial infarction, pulmonary embolism, and thrombophlebitis.

The use of unopposed estrogens in women with intact uteri has been associated with an increased risk of endometrial cancer. The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12- fold greater than in non-users, and appears dependent on duration of treatment and on estrogen dose.

The use of estrogens and progestins by postmenopausal women has been reported to increase the risk of breast cancer.

In the Women's Health Initiative Memory Study (WHIMS) with 4,532 generally healthy postmenopausal women 65 years of age and older were studied, it was observed after an average follow-up of 4 years, 40 women being treated with CE/MPA (1.8%, n = 2,229) and 21 women in the placebo group (0.9%, n = 2,303) received diagnoses of probable dementia. The relative risk for CE/MPA versus placebo was 2.05.

A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.

Estrogen administration may lead to severe hypercalcemia in patients with breast cancer and bone metastases. If hypercalcemia occurs, use of the drug should be stopped and appropriate measures are taken to reduce the serum calcium level.

Retinal vascular thrombosis has been reported in patients receiving estrogens. Discontinue administration of this medicine pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia or a migraine. If examination reveals papilledema or retinal vascular lesions, estrogens should be permanently discontinued.

Progynova (Estradiol Valerate Tablets) Side Effects

The following side effects have been reported in users of various oral HRT preparations including Progynova :

• signs of allergy such as rash, swelling of the face, lips, mouth, throat or other parts of the body, shortness of breath, wheezing or trouble breathing
• changes in body weight
• feeling depressed and/or anxious
• changes in sexual drive
• visual disturbances such as partial or complete loss of vision, bulging eyes, double vision
• intolerance to contact lenses
• irregular heartbeat
• muscle cramps
• changes in vaginal bleeding pattern including spotting
• painful menstrual periods
• vaginal secretion
• premenstrual-like syndrome such as mood swings, bloating, breast swelling and tenderness
• breast pain
• indigestion
• nausea
• vomiting
• stomach pain
• increased appetite
• rash
• various skin disorders such as itching, hives, acne, excessive hairiness, hair loss or red, painful lumps
• headache
• migraine
• dizziness
• swelling of the hands, ankles or feet
• feeling tired

Progynova Overdosage

Serious adverse effects have not been reported following acute ingestion of large doses of estrogen-containing oral contraceptives by young children. Overdosage of estrogen may cause nausea and vomiting, and withdrawal bleeding could occur in females.

Estradiol Valerate During Pregnancy

Estradiol Valerate (Progynova Tablets) has been classified by the US FDA as Pregnancy Category X. Estradiol should not be used during pregnancy. There appears to be little or no increased risk of birth defects in children born to women who inadvertently used estrogens during early pregnancy. Stop using this medication and inform your doctor immediately if you become pregnant during treatment.

Progynova Nursing Considerations

Estradiol (Progynova Tablets) has been detected in human breast milk. Estradiol can decrease the quality or quantity of breast milk. A choice should be made whether to stop nursing or to stop use of this medication.
Do not use this medication without telling your doctor if you are breast-feeding a baby.

Buy Progynova 1 mg and 2 mg Pills Online at Only $0.50 per Pill

You can buy Progynova 1 mg and 2 mg tablets online from Clear Sky Pharmacy at a cheap price. Progynova 1 mg and 2 mg pills, manufactured by Zydus Healthcare, India and marketed by Bayer Pharmaceuticals Pvt. Ltd. (Bayer Zydus Pharma) are supplied in a blister strip of 10 tablets. The 1 mg tablets cost only $0.50 per unit when you place an order for 280 tablets.

Disclaimer

The above information is provided to the best of our knowledge and in good faith, it is without a warrant of any kind, expressed or implied.

Shipping Restriction